Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575]

  • In development
  • GID-TA11742
  • Expected publication date: 
To appraise the clinical and cost effectiveness ofAficamten within its marketing authorisation for treating hypertrophic cardiomyopathy ID6575